The board of Genentech is near a deal to sell the biotech company for $95 a share to suitor Roche. The two sides are still negotiating final terms of the $46.7 billion deal.
WSJ.com: What's News US, Wall Street Journal
Mon, 03/09/2009 - 11:29am
The board of Genentech is near a deal to sell the biotech company for $95 a share to suitor Roche. The two sides are still negotiating final terms of the $46.7 billion deal.